PMID- 18042650
OWN - NLM
STAT- MEDLINE
DCOM- 20080410
LR  - 20220330
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 93
IP  - 2
DP  - 2008 Feb
TI  - Measurements of islet function and glucose metabolism with the dipeptidyl 
      peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
PG  - 459-64
AB  - OBJECTIVE: Pharmacological inhibition with the dipeptidyl peptidase 4 (DPP-4) 
      inhibitor vildagliptin prolongs the action of endogenously secreted incretin 
      hormones leading to improved glycemic control in patients with type 2 diabetes 
      mellitus (T2DM). We undertook a double-blinded, randomized-order, crossover study 
      to examine the vildagliptin mechanisms of action on islet function and glucose 
      utilization. RESEARCH DESIGN AND METHODS: Participants with T2DM (n = 16) who had 
      a baseline hemoglobin A(1c) of 7.1 +/- 0.2% completed a crossover study with 6 wk 
      of treatment with vildagliptin and 6 wk with placebo. At the completion of each 
      arm, participants had a study of postprandial metabolism and a two-step glucose 
      clamp performed at 20 and 80 mU/min x m(2) insulin infusions. RESULTS: 
      Vildagliptin increased postprandial glucagon-like peptide-1 and glucose-dependent 
      insulinotropic polypeptide by 3- and 2-fold, respectively, reduced fasting plasma 
      glucose and postprandial plasma glucose by 1.3 +/- 0.3 mmol/liter and 1.6 +/- 0.3 
      mmol/liter (both P <0.01), and improved glucose responsiveness of insulin 
      secretion by 50% (P < 0.01). Vildagliptin lowered postprandial glucagon by 16% (P 
      <0.01). Examined by glucose clamp, insulin sensitivity and glucose clearance 
      improved after vildagliptin (P < 0.01). CONCLUSIONS: Vildagliptin improves islet 
      function in T2DM and improves glucose metabolism in peripheral tissues.
FAU - Azuma, Koichiro
AU  - Azuma K
AD  - Division of Endocrinology and Metabolism, Department of Medicine, University of 
      Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA.
FAU - Radikova, Zofia
AU  - Radikova Z
FAU - Mancino, Juliet
AU  - Mancino J
FAU - Toledo, Frederico G S
AU  - Toledo FG
FAU - Thomas, Ernestine
AU  - Thomas E
FAU - Kangani, Cyrous
AU  - Kangani C
FAU - Dalla Man, Chiara
AU  - Dalla Man C
FAU - Cobelli, Claudio
AU  - Cobelli C
FAU - Holst, Jens J
AU  - Holst JJ
FAU - Deacon, Carolyn F
AU  - Deacon CF
FAU - He, Yanling
AU  - He Y
FAU - Ligueros-Saylan, Monica
AU  - Ligueros-Saylan M
FAU - Serra, Denise
AU  - Serra D
FAU - Foley, James E
AU  - Foley JE
FAU - Kelley, David E
AU  - Kelley DE
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20071127
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Insulin)
RN  - 0 (Nitriles)
RN  - 0 (Pyrrolidines)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - I6B4B2U96P (Vildagliptin)
RN  - IY9XDZ35W2 (Glucose)
RN  - PJY633525U (Adamantane)
SB  - IM
CIN - J Clin Endocrinol Metab. 2008 Feb;93(2):375-7. PMID: 18258781
MH  - Adamantane/*analogs & derivatives/therapeutic use
MH  - Blood Glucose/metabolism
MH  - C-Reactive Protein/metabolism
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy/*metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Gastric Inhibitory Polypeptide/blood
MH  - Glucagon-Like Peptide 1/blood
MH  - Glucose/*metabolism
MH  - Humans
MH  - Insulin/blood
MH  - Islets of Langerhans/drug effects/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Nitriles/*therapeutic use
MH  - Postprandial Period
MH  - Pyrrolidines/*therapeutic use
MH  - Vildagliptin
EDAT- 2007/11/29 09:00
MHDA- 2008/04/11 09:00
CRDT- 2007/11/29 09:00
PHST- 2007/11/29 09:00 [pubmed]
PHST- 2008/04/11 09:00 [medline]
PHST- 2007/11/29 09:00 [entrez]
AID - jc.2007-1369 [pii]
AID - 10.1210/jc.2007-1369 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2008 Feb;93(2):459-64. doi: 10.1210/jc.2007-1369. Epub 
      2007 Nov 27.